Lemke, J
von Karstedt, S
Zinngrebe, J
Walczak, H
Article History
Received: 17 February 2014
Revised: 14 April 2014
Accepted: 15 April 2014
First Online: 20 June 2014
Competing interests
: HW is a named inventor on the patent that formed the basis for the development of Conatumumab. HW is cofounder, scientific advisor and shareholder of Apogenix GmbH (Heidelberg, Germany), a company that develops apoptosis-based drugs, including the TRAIL-R agonist APG350. The remaining authors declare no conflict of interest.